| 摘要 |
PCT No. PCT/US92/04362 Sec. 371 Date Jan. 24, 1994 Sec. 102(e) Date Jan. 24, 1994 PCT Filed May 27, 1992 PCT Pub. No. WO93/24133 PCT Pub. Date Dec. 9, 1993The invention provides novel chimeric tRNALYS-ribozyme molecules that compete effectively with tRNALYS for HIV-1 reverse transcriptase binding sites. The chimeric human tRNALYS-ribozymes inhibit reverse HIV transcription by delivering inhibitors such as ribozymes of HIV-1 reverse transcriptase directly to the virion particle and render it non-functional. The chimeric molecules of the invention thus serve as highly specific non-toxic therapeutic agents. These chimeric molecules also reveal a novel, site specific RNA cleaving activity of HIV-1.
|
